Literature DB >> 31014825

Comparison of surgical margins for lentigo maligna versus melanoma in situ.

Joy H Kunishige1, Linda Doan2, David G Brodland2, John A Zitelli2.   

Abstract

BACKGROUND: Multiple studies have shown a 5-mm surgical margin to be inadequate for excision of melanoma in situ. Some have suggested that a wider margin is needed only for the lentigo maligna subtype.
OBJECTIVE: To compare subclinical extension of lentigo maligna with that of melanoma in situ. The secondary objective was to investigate the effect of other factors on extent of subclinical extension.
METHODS: A prospectively collected series of noninvasive melanomas was studied. Original pathology reports were used to identify lentigo maligna and compare data for that subtype with data for the remaining melanomas in situ.
RESULTS: A total of 1506 lentigo maligna cases and 829 melanomas in situ were included. To obtain a 97% clearance rate, both lentigo maligna and melanoma in situ required a 12-mm margin on the head and neck and a 9-mm margin on the trunk and extremities. Only 79% of lentigo maligna and 83% of melanoma in situ were successfully excised with a 6-mm margin (P = .12). Local recurrence was identified in 0.26% (5 facial, 1 scalp, and 1 acral), with a mean follow-up time of 5.7 years. LIMITATIONS: Margins less than 6 mm were not studied. The use of lentigo maligna diagnosis was not used by all dermatopathologists consistently. The degree of surrounding photodamage was not assessed.
CONCLUSION: Subclinical extension of lentigo maligna and melanoma in situ are similar. Standard surgical excision of all melanoma in situ subtypes, including lentigo maligna, should include at least 9 mm of normal-appearing skin, which is similar to the amount recommended for early invasive melanoma. Lesions on the head and neck or those with a diameter greater than 1 cm may require even wider margins and are best treated with Mohs micrographic surgery. The perception that lentigo maligna has wider subclinical extension may be related to its frequent location on the head and neck, where photodamage can camouflage the clinical border.
Copyright © 2019 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Mohs micrographic surgery; excision; guidelines; lentigo maligna; melanoma; melanoma in situ

Mesh:

Year:  2019        PMID: 31014825     DOI: 10.1016/j.jaad.2019.01.051

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  6 in total

Review 1.  Treatment of periocular lentigo maligna with topical 5% Imiquimod: a review.

Authors:  Inga Neumann; R Patalay; M Kaushik; H Timlin; C Daniel
Journal:  Eye (Lond)       Date:  2022-07-14       Impact factor: 4.456

2.  Lentigo Maligna of the head and neck: A retrospective study assessing surgical excision margins in a South African population.

Authors:  Johann de Wet; Pieter J du Plessis; Johann W Schneider
Journal:  JAAD Int       Date:  2022-04-28

Review 3.  Evidence from Clinical Studies Related to Dermatologic Surgeries for Skin Cancer.

Authors:  Shoichiro Ishizuki; Yoshiyuki Nakamura
Journal:  Cancers (Basel)       Date:  2022-08-08       Impact factor: 6.575

4.  Association between excision margins and local recurrence in 1407 patients with primary in situ melanomas.

Authors:  Licata Gaetano; Birra Domenico; Serigne N Lo; Tasnia Hamed; Alison J Potter; John F Thompson; Richard A Scolyer; Pascale Guitera
Journal:  JAAD Int       Date:  2022-06-16

Review 5.  Melanoma In Situ: A Critical Review and Re-Evaluation of Current Excision Margin Recommendations.

Authors:  Erica B Friedman; Richard A Scolyer; Gabrielle J Williams; John F Thompson
Journal:  Adv Ther       Date:  2021-05-28       Impact factor: 3.845

6.  Re: Reply to letter to the editor re: 'practical guide on the use of imiquimod cream to treat lentigo maligna'.

Authors:  Pascale Guitera; Andreanne Waddell; Elizabeth Paton; Gerald B Fogarty; Angela Hong; Richard A Scolyer; Jonathan R Stretch; Brett A O'Donnell; Giovanni Pellacani
Journal:  Australas J Dermatol       Date:  2022-02-02       Impact factor: 2.481

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.